Intracellular filamentous tau aggregates are closely associated with the severity of brain dysfunction and neuronal loss (Arriagada et al., 1992), and therefore, approaches to attenuating tau aggregation can be a major therapeutic strategy for the treatment of several neurodegenerative diseases (Jadhav et al., 2019). Here, MAPT is linked to neurodegenerative disease.